Kyverna Therapeutics在欧洲风湿病学大会（EULAR）上公布了其CAR-T细胞疗法候选药物miv-cel（KYV-101）的更新数据。数据显示，在接受治疗的抗瓜氨酸蛋白抗体（ACPA）阳性、且对现有疗法反应不佳的难治性类风湿关节炎（RA）患者中，该疗法能显著降低疾病活动度。
此次公布的数据进一步证实了miv-cel在这一患者群体中的潜力。分析显示，患者的疾病活动度评分出现具有临床意义的下降，表明该疗法可能为传统治疗手段无效的类风湿关节炎患者提供一种新的治疗选择。
Kyverna Therapeutics专注于开发用于自身免疫性疾病的工程化T细胞疗法。公司表示，这些积极数据支持了miv-cel的持续临床开发计划，旨在解决严重自身免疫性疾病领域未被满足的医疗需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.